

Resignation of Mr Alex Sundich

Adelaide, Australia, 24 November 2021 – Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, announces that Mr Alex Sundich has resigned as a non-executive director of Nova Eye Medical, effective immediately. Mr Sundich has been a Board member since 2006.

Commenting on Mr Sundich’s decision, Chairman Victor Previn stated “I have worked with Alex for a long time and have enjoyed it greatly. His time on the Board has been a major contribution to our Company”.

“Soon after joining the Board, Alex provided valuable management and financial contributions to the business during the global financial crisis when the Company faced considerable difficulty. Following that he guided the business through the growth of the Laser & Ultrasound business and ultimately to its sale last year to Lumibird for \$100m. Alex was an early advocate for the investments we have made in both 2RT, our ophthalmic laser for intermediate age related macular degeneration and iTrack™, our glaucoma surgical device and continues to believe in the business’s future. Alex’s material shareholding supports his conviction”. Added Mr Previn.

On his resignation Mr Sundich said “Nova Eye is a wonderful business that delivers products that improve people’s lives. I have enjoyed being part of the team but after 15 years on the Board it is time to step aside.. I look forward to closely following the Company as it continues to successfully execute its growth strategy”.

This release dated 24 November 2021 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
Nova Eye Medical Limited
W +61 417 818 658
tspurling@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com